Depression Related Improvement With Vardenafil for Erectile Response

NCT00661219 | Completed Phase 3

• 1 other identifier: 10621
• Study Type: interventional
• Target: 280
• Locations: 5 countries
• Sites: 52

Brief Summary

The study will last three months. During the first month of treatment the subject will receive either 10 mg vardenafil or placebo. After 1 month of treatment the doctor, can choose to increase the dosage from 10 mg to 20 mg or decrease the dosage to 5 mg. The doctor will again evaluate, after 2 months of treatment if the subject wants to increase the dosage from 10 mg to 20 mg or, if already done, to continue with the dosage of 20 mg or decrease to 10 mg or 5 mg. It will not be possible after this point to increase or decrease the dosage for the rest of the study. The subject will be asked to attend the clinic on four separate occasions over a period of 3 months. Every visit will last about 1 hour. At the first visit the doctor will ask the subject about their medical history, and the subject will be given a medical examination (including your heart rate, blood pressure and weight). The medical examination will also include an ECG. The subject will be asked to provide a blood and urine sample, which will be analysed and screened for drugs of potential abuse (e.g.cocaine, narcotics, sedatives, hypnotics). The subject will then be asked to fill in a questionnaire about their mood and feelings. The subject qualifies, they will have an interview with a trained mental health care provider who will assess their level of depression. At the end of the visit, the doctor will provide the subject with a diary in which they must record details about their attempts at sexual activity during the next 4 weeks. The subject will be asked to make at least 4 attempts at sexual intercourse on 4 separate days and to record the attempts in the diaries. After 4 weeks the subject will return to the clinic. They will be asked to fill in different questionnaires about their sexuality, mood and feelings, general quality of life, self-esteem and sexual activity in the last 4 weeks. Two additional blood and urine samples will be collected. An interview with the trained mental health care provider who will re-assess their level of depression. At this visit all information collected so far will be assessed and the doctor will check to see if the requirements to enter the treatment period are fulfilled. The subject may be excluded from further participation in the study, for example due to results of the blood analysis or if your level of depression did not meet the criteria for the study. If the subject is able to participate to the study they will be given the study drug. At each visit, adverse events will be discussed and whether there is any change in medicine. Vital signs and ECG will be obtained at visit one, two, five and/or Premature Termination. At every visit the subject will receive a diary in which they must record details about their attempts at sexual activity during the period between each visit and the number of tablets taken. Subjects will also be asked to fill in different questionnaires about their sexuality, mood and feelings, self-esteem and sexual activity. Subjects will also be contacted by telephone, at 2, 6 and 10 weeks after starting the study medication, 24 hours after the last dose of study medication. The doctor will give the study drug on 3 occasions. Should the subject or doctor prematurely stop trial participation the subject will be required to return to the clinic for a physical examination, vital signs and have blood samples and ECG obtained. They will also be asked to fill in different questionnaires.

Conditions

Erectile Dysfunction; Depression

Outcome Measures

Primary Outcomes (1)

• The primary efficacy variables are the change from baseline in the IIEF-EF domain score and the change from baseline in the HAM-D17 total score.

  12 weeks and LOCF

Secondary Outcomes (9)

• Patient Diary questions of treatment compared to placebo.

  4, 8, and 12 weeks

• Global assessment question (GAQ) of treatment compared to placebo.

  12 weeks

• The scores for the IIEF questionnaire.

  12 weeks

• Responses on the Center for Epidemiologic Studies Depression Scale (CES-D).

  12 weeks

• Responses on the Rosenberg Self Esteem Scale.

  12 weeks

Study Arms (2)

Arm 1

ACTIVE COMPARATOR

Drug: Levitra (Vardenafil, BAY38-9456)

Arm 2

PLACEBO COMPARATOR

Drug: Placebo

Interventions

Levitra (Vardenafil, BAY38-9456) DRUG

BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.

Arm 1

Placebo DRUG

Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.

Arm 2

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Erectile dysfunction for more than 6 months according to the NIH Consensus statement (the inability to attain and maintain erection of the penis sufficient to permit satisfactory sexual intercourse).
• Stable, heterosexual relationship for more than 6 months.
• Diagnosis of mild Major Depressive Disorder using a structured interview (SCID-1 or MINI), according to DSM-IV criteria. Before randomization, a psychiatrist must interview the subject at Visit 2 to validate both the diagnosis of MDD and the subject's continuation in the study without the need for anti-depressant medication or psychotherapy).
• Patients must score greater than 13 on the CES-D at Visit 1.
• Patients must score between 11 and 17 on the 17-item HAM-D at Visit 1 and Visit 2.
• The patient must make at least four attempts at sexual intercourse on four separate days during the untreated baseline period
• At least 50% of the attempts of sexual intercourse during the untreated baseline period have to be unsuccessful

You may not qualify if:

• Previous or Current Medical Conditions
• Any unstable medical condition or substance abuse disorder that, in the opinion of the Investigator, is likely to affect the patient's ability to complete the study or precludes the patient's participation in the study.
• Patients who score \> 0 on item #3 on the HAM-D17 or men who, in the investigator's judgement, pose a current serious suicidal or homicidal risk or have made a suicide attempt within the past 12 months.
• Men with a current (or within 6 months prior to screening) Axis 1 disorder other than MDD (major depressive disorder). Patients with a history, or who currently meet the DSM-IV criteria, of Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Delusional (Paranoid) Disorder, Panic Disorder, Post-Traumatic Stress Disorder. Patients with a Personality Disorder are excluded if, in the investigator's opinion, it will interfere with the conduct of the trial.
• Retinitis pigmentosa.
• Unstable angina pectoris.
• History of radical prostatectomy.
• History of myocardial infarction, stroke, electrocardiographic ischemia (except stable angina), or life-threatening arrhythmia within the prior 6 months.
• Abnormal Laboratory Values
• AST or ALT \> 3 times the upper limit of normal Concomitant Medications
• Patients who are taking nitrates or nitric oxide donors (e.g., molsidomine, minoxidil). Topical minoxidil is permitted.
• Patients who are taking androgens (e.g., testosterone) or anti-androgens.
• Patients taking trazodone, or any other anti-depressant including monoamine oxidase inhibitors, St. John's Wort, SSRIs or tricyclic anti-depressants are excluded, or use of these medications in the last 2 weeks before Visit 1. Fluoxetine is excluded in the last 4 weeks before Visit 1.
• Patients who are taking the following potent inhibitors of cytochrome P 450 3A4: the HIV protease inhibitors ritonavir and indinavir, erythromycin or the anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed).
• Subjects who are taking alpha-blockers.

Sponsors & Collaborators

• Bayer: lead

Study Sites (52)

Unknown Facility

Huntsville, Alabama, 35801, United States

Location

Unknown Facility

Anchorage, Alaska, 99508, United States

Location

Unknown Facility

Beverly Hills, California, 90212, United States

Location

Unknown Facility

Irvine, California, 92618-3603, United States

Location

Unknown Facility

La Mesa, California, 91942-3058, United States

Location

Unknown Facility

San Diego, California, 92101, United States

Location

Unknown Facility

Aventura, Florida, 33180, United States

Location

Unknown Facility

Atlanta, Georgia, 30308, United States

Location

Unknown Facility

Atlanta, Georgia, 30339, United States

Location

Unknown Facility

Boston, Massachusetts, 02118, United States

Location

Unknown Facility

New Brunswick, New Jersey, 08901, United States

Location

Unknown Facility

Albuquerque, New Mexico, 87131, United States

Location

Unknown Facility

New York, New York, 10032, United States

Location

Unknown Facility

Durham, North Carolina, 27710, United States

Location

Unknown Facility

Charlottesville, Virginia, 22908, United States

Location

Unknown Facility

Calgary, Alberta, T2S 0J2, Canada

Location

Unknown Facility

Edmonton, Alberta, T5K 2K5, Canada

Location

Unknown Facility

Vancouver, British Columbia, V5Z 1M9, Canada

Location

Unknown Facility

Hamilton, Ontario, L8M 1K7, Canada

Location

Unknown Facility

Markham, Ontario, L6B 1A1, Canada

Location

Unknown Facility

Ottawa, Ontario, K1G 4G3, Canada

Location

Unknown Facility

Toronto, Ontario, M9W 4L6, Canada

Location

Unknown Facility

Hull, Quebec, J9A 1K7, Canada

Location

Unknown Facility

Montreal, Quebec, H2X 1N8, Canada

Location

Unknown Facility

Montreal, Quebec, H3G 1A4, Canada

Location

Unknown Facility

Pointe-Claire, Quebec, H9R 4S3, Canada

Location

Unknown Facility

Sherbrooke, Quebec, JIH 4J6, Canada

Location

Unknown Facility

Lille, 59000, France

Location

Unknown Facility

Lyon, 69000, France

Location

Unknown Facility

Lyon, 69007, France

Location

Unknown Facility

Lyon, 69437, France

Location

Unknown Facility

Marseille, 13006, France

Location

Unknown Facility

Marseille, 13008, France

Location

Unknown Facility

Marseille, 13275, France

Location

Unknown Facility

Nantes, 44000, France

Location

Unknown Facility

Nice, 06200, France

Location

Unknown Facility

Paris, 75009, France

Location

Unknown Facility

Bari, 70124, Italy

Location

Unknown Facility

Florence, 50139, Italy

Location

Unknown Facility

Milan, 20122, Italy

Location

Unknown Facility

Milan, 20123, Italy

Location

Unknown Facility

Milan, 20132, Italy

Location

Unknown Facility

Modena, 41100, Italy

Location

Unknown Facility

Napoli, 80131, Italy

Location

Unknown Facility

Padua, 35128, Italy

Location

Unknown Facility

Pisa, 56126, Italy

Location

Unknown Facility

Roma, 00155, Italy

Location

Unknown Facility

Barcelona, Barcelona, 08036, Spain

Location

Unknown Facility

Galdakao, Bizkaia, 48960, Spain

Location

Unknown Facility

Madrid, Madrid, 28007, Spain

Location

Unknown Facility

Seville, Sevilla, 41013, Spain

Location

Unknown Facility

Zaragoza, Zaragoza, 50009, Spain

Location

MeSH Terms

Conditions

Erectile Dysfunction; Depression

Interventions

Vardenafil Dihydrochloride

Condition Hierarchy (Ancestors)

Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Sexual Dysfunction, Physiological; Male Urogenital Diseases; Sexual Dysfunctions, Psychological; Mental Disorders; Behavioral Symptoms; Behavior

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Piperazines

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 15, 2008
• First Posted: April 18, 2008
• Study Start: December 1, 2002
• Primary Completion: November 1, 2003
• Study Completion: November 1, 2003
• Last Updated: December 23, 2014

Record last verified: 2014-12

Locations

ES (5); CA (12); US (15); FR (10); IT (10)